Vol. 5 No. 12 (2025)
Reimbursement Recommendations

Delgocitinib (Anzupgo)

decorative image of the issue cover

Published December 1, 2025

Key Messages

  • Canada’s Drug Agency (CDA-AMC) recommends that Anzupgo be reimbursed by public drug plans for the treatment of moderate to severe chronic hand eczema (CHE), if certain conditions are met.
  • Anzupgo should only be covered to treat adults (aged ≥ 18 years) with moderate to severe CHE who have had an inadequate response to, or cannot use, topical corticosteroids (TCSs). Patients must have tried appropriate topical therapy (emollients with or without TCSs) before starting Anzupgo.
  • Anzupgo should only be reimbursed for patients who have received an adequate trial of appropriate topical therapy, when prescribed by — or in consultation with — a dermatologist or clinician experienced in the management of CHE, and the cost of Anzupgo should not exceed the total drug cost of alitretinoin.